Three TNBC PDXs (BRCA1‑mutated, PTEN‑null, PI3K‑wild‑type) were implanted subcutaneously into NOD/SCID mice (n = 8/group). Dosing regimens mirrored the orthotopic study. Survival was defined as time to tumor volume ≥ 1500 mm³.
Data are presented as mean ± SD. Comparisons between groups used one‑way ANOVA with Tukey’s post‑hoc test or log‑rank test for survival. Synergy was evaluated using the Chou–Talalay method (Combination Index < 1 indicates synergism). P‑values < 0.05 were considered statistically significant. MEYD-773